Differential prognostic factors in low‐ and high‐burden de novo metastatic hormone‐sensitive prostate cancer patientsMasaki Shiota, Takahiro Kimura, Ken‐ichi Tabata et al.|Cancer Science|2020Cited by 48
Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancerMasaki Shiota, Naoki Terada, Hiroshi Kitamura et al.|Cancer Science|2021Cited by 15
Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy on the Prognosis of Muscle‐Invasive Bladder Cancer Treated With Radical CystectomyShingo Hatakeyama, Rikiya Taoka, Jun Miki et al.|Cancer Medicine|2025Cited by 8
Stage <scp>III</scp> substaging and outcomes in patients with bladder cancer undergoing radical cystectomyShuhei Hara, Wataru Fukuokaya, Jun Miki et al.|International Journal of Urology|2025Cited by 7
Efficacy of cisplatin-based neoadjuvant chemotherapy and risk factors for residual extravesical disease in muscle-invasive bladder cancer: insights from a nationwide cohortRyoichi Saito, Rikiya Taoka, Jun Miki et al.|International Journal of Clinical Oncology|2025Cited by 5